# PANACRO

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/panacro

- Industry: Pharmaceuticals
- Headquarters: Hefei, China
- Website: www.panacro.com
- Total disclosed funding: $14M
- Latest round: Series B (Dec 18, 2023)
- Investors on record: 2

## About

Founded in 2004 and based in Beijing, China, PANACRO is a medical services company that focuses on pharmaceutical R&D and clinical research CRO services. It was recognized as a National High-tech enterprise. Min Zhao, the CEO and the founder of the company, used to work in clinical research at the Boehringer Ingelheim Medical Registry. The company has four subsidiaries in Suzhou and other cities. In December 2023, PANACRO raised a series B1 funding for approximately CNY 100 million.

The company's main business is to provide services related to clinical research and registration filing for chemical drugs, biological drugs, and vaccines. Its services include Phase I-IV clinical trials, data management, statistical analysis for pharmaceutical product development, and other related services. Its service clients include Guangzhou Phar.Holdings, NEPTUNUS, Henlius, and other enterprises.

The company will use the funding for the advancement of internationalization and digital intelligence business, as well as the expansion of the North American and Southeast Asian markets.

## Funding rounds

- Series B, Dec 18, 2023, $14M — CoStone Capital, Jinyuan Kuntong Equity Investment Management

## Investors

- CoStone Capital (https://capitalatlas.ai/funds/costone-capital) — Series B
- Jinyuan Kuntong Equity Investment Management (https://capitalatlas.ai/funds/jinyuan-kuntong-equity-investment-management) — Series B